AnnieJKrugerMDPhD

Hepatology & Liver Transplantation

Clinical Research Director, Immunology and Inflammation, Sanofi

Dr. Kruger is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Dr. Annie Kruger is a Clinical Research Director in Immunology and Inflammation Early Development at Sanofi. She received her medical degree from University of Massachusetts Medical School and completed her residency and fellowship at Massachusetts General Hospital. She was a practicing gastroenterologist and hepatologist at MedStar Georgetown University Hospital prior to joining Sanofi.

PubMed

50 citations
Blockade of the programmed death-1 (PD1) pathway undermines potent genetic protection from type 1 diabetes.
Nora Kochupurakkal, Annie J. Kruger, Sudipta Tripathi, Bing Zhu, La Tonya Adams
Plos One. 2014-02-28
11 citations
Hepatitis B and Hepatitis C Virus Infection Promote Liver Fibrogenesis through a TGF-β1-Induced OCT4/Nanog Pathway.
Wenting Li, Xiaoqiong Duan, Chuanlong Zhu, Xiao Liu, Andre J Jeyarajan
Journal of Immunology. 2022-02-01
27 citations
Fatty acids activate the transcriptional coactivator YAP1 to promote liver fibrosis via p38 mitogen-activated protein kinase.
Shadi Salloum, Andre J Jeyarajan, Annie J. Kruger, Jacinta A Holmes, Tuo Shao
Cellular and Molecular Gastroenterology and Hepatology. 2021-01-01

Journal Articles

Macrophage Activation Marker Soluble CD163 Is a Dynamic Marker of Liver Fibrogenesis in HIV/HCV Coinfection
Ma Somsouk, Eoin R Feeney, Raymond T Chung, Steven Deeks, Annie J Kruger, Ricard Masia, Kathleen E Corey, Esperance A Schaefer, The Journal of Infectious Diseases